Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Articles by Paul Hagopian, Chief Growth Officer, Fingerpaint Group
Advertisement
Latest Updated Articles
- The opportunity to evolve the oncology model is ready and waiting
Published: June 1st 2023 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Roche’s Refresh
2
FDA Approves Novo Nordisk’s Wegovy Pill for Weight Management
3
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
4
Data Quality in Drug Development: The Missing Foundation to Realize AI’s Promise in Clinical Trials
5